1. Sjögren E, Bolger MB, Lukacova V, Weitschies W, Wilson C, Augustijns P, et al. In vivo methods for drug absorption and API/dosage forms studies. Eur J Pharm Sci. Under revision.
2. Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2013 Aug 27. doi: 10.1016/j.ejps.2013.08.024
3. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for Industry: Immediate release solid oral dosage forms, scale-up and postapproval changes: Chemistry, Manufacturing, and Controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995. CMC 5.
4. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for Industry: SUPAC-MR: Modified release solid oral dosage forms, scale-up and postapproval changes: Chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation, September 1997a. CMC 8.
5. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for Industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo, correlations, September 1997b. BP 2. http://www.fda.gov/cder/guidance/index.htm